Attendee search 

Avisa Pharma™ Inc., (AVISA) is a Point Of Care, In-Vivo Platform Technology Company With An Innovative, Integrated System For The Rapid Detection And Monitoring Of Respiratory Diseases. A paradigm shift away from lab based In Vitro testing; an In Vivo, point of care, breath test that measures the whole lung, live organisms, not a single culture sample in a petri dish or PCR;for non sputum producers - the only test that can detect lung bacteria without a sputum culture; A razor/razorblade Model to Drive Rapid Market Penetration and Growth.

Focused initially on respiratory health, the clinical study strategy is to pursue fastest route to regulatory approvals, the detection of Tuberculosis (TB), followed by Healthcare Acquired Pneumonia (HCAP), Ventilator Associated Pneumonia (VAP), Cystic Fibrosis (CF) and COPD. These applications have the potential to help save millions of lives and millions of dollars in healthcare costs each year, and a multi billion $ market opportunity.  

$6 million Series A1 Preferred round underway, $4 million received from current investors exercising preemptive rights. Q1 2015 Avisa will be launching a 40 patient pilot TB study in South Africa.

Ischemia Care (ISC) is a clinical stage, capital efficient, venture capital backed, diagnostic laboratory company commercializing ISCDX, a blood test for cause of ischemic stroke (including atrial fibrillation or “AF”), leading to timely diagnosis and treatment, resulting in hospital cost savings and improved patient outcomes. ISC is executing on the Biomarkers of Acute Stroke Etiology (BASE) study , clinicaltrials.gov identifier NCT02014896 to support clinical adoption as an LDT through a company owned CLIA laboratory. ISC's initial focus is on the 40% (320K annually) ischemic strokes which are diagnosed as unkown cause (or "cryptogenic") as these patients typically are undertreaked and at a high risk for recurrence.

Stroke is the third leading cause of death worldwide with 20M annual events. In the US, there are 800K strokes, of which 195K are recurrent. Despite advances in imaging, cardiac monitoring, patient history assessment, and clinical examination, in 40% of ischemic strokes, the cause is unknown (or “cryptogenic”) leading to high recurrence and death.  There are no blood tests for cause of stroke. The identification of cause will change outcomes per Stroke Guidelines by adoption of “cause based” treatment regimen to prevent a more massive, debilitating, and costly recurrence. For example, identifying “undetected” AF in cryptogenic patients provides a 60% risk recurrence reduction.

McDermott Will & Emery is a premier international law firm with a unique focus in representing life sciences companies and investors in a wide variety of transactional, intellectual property and regulatory matters.  Through our Life Sciences Entrepreneurs Acceleration Program ("LEAP") we provide early stage medical device, pharmaceutical, biotechnology and diagnostic companies access to sophisticated legal services.  Learn more here: http://www.mwe.com/leap/

VC fund focusing on investments in Switzerland and surounding areas

We are a Hong Kong-based venture fund management company focusing on mid- to long-term advanced technology investments at early stage. Through our partnership with the top analytical companies utilizing machine learning and large panel of experts, we can construct complex decision trees showing risk and return at every stage of company evolution. We routinely invest in both private and public companies specializing in biotechnology, drug discovery, personalized medicine, Big Data analysis, industrial expert systems and artificial intelligence. 

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Development-stage pharmaceutical company with a platform technology to deliver novel therapeutics to the urinary bladder lumen for the treatment of inflammatory bladder conditions such as overactive bladder and interstitial cystitis. Our portfolio includes prodcuts in pase-I and phase-II clinical trials in the United States and overseas, as well as pre-clinical programs. We also have one program designated as orphan. In addition to therapeutics, Lipella also develops diagnostic agents to be used in connection with medical imaging.

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA.